{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:51:02Z","timestamp":1784296262886,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vhri.2018.11.002","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T23:26:13Z","timestamp":1546989973000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The Burden of Macular Diseases in Central and Eastern Europe\u2014Implications for Healthcare Systems"],"prefix":"10.1016","volume":"19","author":[{"given":"Polona","family":"Jaki Mekjavi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"J\u016brat\u0117 Bal\u010di\u016bnien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lala","family":"\u0106ekli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ernest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Jamrichova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Zsolt Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Petkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Garda\u0161evi\u0107 Top\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vhri.2018.11.002_bib1","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990-2010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob Health"},{"issue":"24","key":"10.1016\/j.vhri.2018.11.002_bib2","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vhri.2018.11.002_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s13770-012-0374-0","article-title":"Age-related macular degeneration (AMD): current concepts in pathogenesis and prospects for treatment","volume":"10","author":"Shin","year":"2013","journal-title":"Tissue Eng Regen Med"},{"issue":"1","key":"10.1016\/j.vhri.2018.11.002_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eurger.2014.09.007","article-title":"Age related macular degeneration\u2014challenge for future: pathogenesis and new perspectives for the treatment","volume":"6","author":"Michalska-Mal\u00e9ecka","year":"2015","journal-title":"Eur Geriatr Med"},{"issue":"6","key":"10.1016\/j.vhri.2018.11.002_bib5","first-page":"900","article-title":"AMD\u2014the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics","volume":"71","author":"Nowak","year":"2014","journal-title":"Acta Pol Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2018.11.002_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.vhri.2018.11.002_bib7","doi-asserted-by":"crossref","first-page":"632307","DOI":"10.1155\/2014\/632307","article-title":"Anti-VEGF for the management of diabetic macular edema","volume":"2014","author":"Stefanini","year":"2014","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.vhri.2018.11.002_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.vhri.2018.11.002_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/11538340-000000000-00000","article-title":"Diabetic macular edema: correlations with available diabetes therapies\u2014evidence across a qualitative review of published literature from MEDLINE and EMBASE","volume":"33","author":"Merante","year":"2010","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.vhri.2018.11.002_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2042018813512360","article-title":"Anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"4","author":"Boyer","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.vhri.2018.11.002_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)","volume":"11","author":"Blinder","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.vhri.2018.11.002_bib13","doi-asserted-by":"crossref","first-page":"510285","DOI":"10.1155\/2014\/510285","article-title":"Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering","volume":"2014","author":"Fernandez-Robredo","year":"2014","journal-title":"J Ophthalmol"},{"issue":"2","key":"10.1016\/j.vhri.2018.11.002_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.vhri.2018.11.002_bib15","series-title":"UEMS survey highlights accessibility disparities, inconsistent policies for anti-VEGF treatment across Europe","first-page":"5","author":"Hawlina","year":"2015"},{"key":"10.1016\/j.vhri.2018.11.002_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"issue":"2","key":"10.1016\/j.vhri.2018.11.002_bib17","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vhri.2018.11.002_bib18","author":"Shanahan"},{"issue":"4","key":"10.1016\/j.vhri.2018.11.002_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/08820538.2017.1316861","article-title":"Prevalence of age-related macular degeneration in Slovakia and associated risk factors: a mobile clinic-based cross-sectional epidemiological survey","volume":"33","author":"Krasnik","year":"2018","journal-title":"Semin Ophthalmol"},{"issue":"8","key":"10.1016\/j.vhri.2018.11.002_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7365\/JHPOR.2016.1.8","article-title":"Diabetic macular edema treatment limits in Poland","volume":"1","author":"Pinkas","year":"2016","journal-title":"J Health Policy Outcomes Res"},{"issue":"12","key":"10.1016\/j.vhri.2018.11.002_bib24","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vhri.2018.11.002_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1477-7525-4-97","article-title":"Quality of life in age-related macular degeneration: a review of the literature","volume":"4","author":"Mitchell","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vhri.2018.11.002_bib28","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2147\/OPTH.S45248","article-title":"Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice","volume":"7","author":"Yuzawa","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.vhri.2018.11.002_bib29","first-page":"109","article-title":"Quality of life in patients with age-related macular degeneration","volume":"48","author":"Siaudvytyte","year":"2012","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"10.1016\/j.vhri.2018.11.002_bib30","doi-asserted-by":"crossref","first-page":"e003471","DOI":"10.1136\/bmjopen-2013-003471","article-title":"The economic burden of visual impairment and blindness: a systematic review","volume":"3","author":"Koberlein","year":"2013","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.vhri.2018.11.002_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/bjo.2006.113142","article-title":"Formal and informal care utilisation amongst elderly persons with visual impairment","volume":"91","author":"Ke","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.vhri.2018.11.002_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/17441692.2011.634815","article-title":"An estimation of the worldwide economic and health burden of visual impairment","volume":"7","author":"Gordois","year":"2012","journal-title":"Glob Public Health"},{"issue":"4","key":"10.1016\/j.vhri.2018.11.002_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/09286586.2017.1281426","article-title":"The economic impact of blindness in Europe","volume":"24","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.vhri.2018.11.002_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40942-015-0016-5","article-title":"A value-based medicine cost-utility analysis of genetic testing for neovascular macular degeneration","volume":"1","author":"Brown","year":"2015","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"10.1016\/j.vhri.2018.11.002_bib39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1524-4733.2007.00283.x","article-title":"Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity","volume":"11","author":"Javitt","year":"2008","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2018.11.002_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"9","key":"10.1016\/j.vhri.2018.11.002_bib43","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.vhri.2018.11.002_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.eye.6703053","article-title":"Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss","volume":"23","author":"Arias","year":"2009","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.vhri.2018.11.002_bib45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","article-title":"Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration","volume":"153","author":"Lim","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.vhri.2018.11.002_bib46","doi-asserted-by":"crossref","first-page":"e0133628","DOI":"10.1371\/journal.pone.0133628","article-title":"The clinical effectiveness and cost-effectiveness of screening for age-related macular degeneration in Japan: a Markov modeling study","volume":"10","author":"Tamura","year":"2015","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.vhri.2018.11.002_bib47","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta12270","article-title":"A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration","volume":"12","author":"Karnon","year":"2008","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.vhri.2018.11.002_bib48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1932296815624109","article-title":"Cost-effectiveness of different diabetic retinopathy screening modalities","volume":"10","author":"Pasquel","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.vhri.2018.11.002_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.01.013","article-title":"Considerations for management of patients with diabetic macular edema: optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration","volume":"126","author":"Strain","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.vhri.2018.11.002_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jval.2017.07.009","article-title":"Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States","volume":"21","author":"Brown","year":"2018","journal-title":"Value Health"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109918303649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109918303649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:10:37Z","timestamp":1761941437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109918303649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"alternative-id":["S2212109918303649"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2018.11.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Burden of Macular Diseases in Central and Eastern Europe\u2014Implications for Healthcare Systems","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}